Dionysus Health and Mammha Announce Groundbreaking Partnership to Transform Postpartum Depression Care Through Precision Diagnostics and Comprehensive Support

San Diego, CA – July 25, 2025 – Qwoted Newswire – Dionysus Health, the molecular diagnostics company behind myLuma, and Mammha, a leading provider of accessible, full-spectrum perinatal mental health care, today announced a groundbreaking partnership to fundamentally reshape how postpartum depression (PPD) is predicted, prevented, and treated.

This first-of-its-kind collaboration combines myLuma—the first predictive prenatal blood test for postpartum depression risk—with Mammha’s clinician-designed care platform, delivering the most complete and proactive maternal mental health solution on the market.

myLuma is the first clinically validated molecular diagnostic that predicts a woman’s risk of PPD with 85% accuracy from a simple third-trimester blood draw. This allows providers to intervene as early as 28 weeks into pregnancy—weeks to months before symptoms may appear. Combined with Mammha’s full continuum of care, the partnership ensures mothers are not only identified early but supported throughout their entire maternal journey.

“This partnership brings together scientific innovation and clinical care to deliver a true end-to-end solution,” said Dr. Andrea Cubitt, CEO of Dionysus Health. “myLuma provides the critical early warning system through molecular diagnostics, while Mammha ensures timely care delivery. We’re moving from reactive treatment to proactive prevention, from uncertainty to precision, and from fragmented efforts to coordinated care.”

“We created Mammha to fill the gaps in the perinatal healthcare system that parents have been falling through for much too long,” said Maureen Fura, CEO of Mammha. “Partnering with Dionysus Health gives us the predictive power we’ve always dreamed of having, so that we can  intervene early and effectively.”

Why This Matters Now

Postpartum depression is one of the most urgent and preventable maternal health crises:

• PPD contributes to almost 1 in 4 maternal deaths
• 75% of affected women receive no treatment
• The U.S. spends over $17 billion annually addressing the consequences
• 96% of U.S. counties face mental health provider shortages
• Only 33% of providers screen for perinatal depression (HEDIS)

“We’re solving for OB providers, health systems, and mothers,” said Alisa Marie Beyer, COO of Dionysus Health. “While screening tools remain essential for identifying current symptoms, until now there’s been no biological diagnostic for PPD to predict risk before symptoms emerge. This partnership brings predictive data and enhanced support tools to enable proactive prevention, earlier intervention, and better outcomes for everyone involved.”

Next Steps for Launch and Growth

The integrated myLuma solution is projected to kick-off in September 2025 with a pilot program involving multiple OB providers across California and Florida, aiming for 100 completed patient tests per month. It is anticipated to grow the pilot to an additional 50 OB providers. The full-scale launch is planned for January 2026, targeting 100 provider offices and serving over 1,000 women monthly.

Dionysus Health is currently managing a growing waitlist of providers and patients ahead of the national rollout.